×

Subscribe Today

Get our free articles delivered directly to your email!

Continue reading

Janux Therapeutics Inc. (JANX) NASDAQ

$40.96 0.66 (1.64%)

Market Cap: $2.12B

As of 06/21/24 04:00 PM EDT. Market closed.

(JANX)

Janux Therapeutics Inc. (JANX)
NASDAQ

$40.96
0.66 (1.64%)

Market Cap: $2.12B

As of 06/21/24 04:00 PM EDT. Market closed.

Add to Portfolio

janux therapeutics is an innovative biopharmaceutical company developing next-generation therapeutics based on its proprietary tumor activated t cell engager (tractr) platform technology to better treat patients suffering from cancer. janux’s initial focus is on developing a novel class of t cell engagers (tces), and its lead product candidates are designed to target clinically validated drug ... read more

COMPANY PROFILE
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
URL
Address
10955 Vista Sorrento Parkway, Suite 200, CA, San Diego, 92130.
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
David Alan Campbell
Address
10955 Vista Sorrento Parkway, Suite 200, CA, San Diego, 92130.
PRICE CHART FOR JANUX THERAPEUTICS INC
1w
1m
3m
6m
YTD
1y
5y
MAX
From: To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$41
Previous Close
$40.30
Days Range
$39.21 - $41.88
52 week range
$5.65 - $65.60
Volume
2,110,881
Avg. Volume (30 days)
907,892
Market Cap
$2.12B
Dividend Yield
-
P/E
(38.20)
Shares Outstanding
51,850,667
Open
$41
Previous Close
$40.30
Days Range
$39.21 - $41.88
52 week range
$5.65 - $65.60
Volume
2,110,881
Avg. Volume (30 days)
907,892
Market Cap
$2.12B
Dividend Yield
-
P/E
(38.20)
Shares Outstanding
51,850,667
FINANCIAL STATEMENTS FOR JANUX THERAPEUTICS INC
LOADING...

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

INSIDER TRANSACTIONS FOR JANUX THERAPEUTICS INC
OwnerRelationshipDateTransactionCost# SharesValue($)Total SharesForm 4
Lichter JayDirectorJun 03, 2024 Sale$54.75691,52537,860,9943,340,018Jun 05, 2024, 07:25 PM
Lichter JayDirectorJun 03, 2024 Sale$54.75131,1967,182,981633,673Jun 05, 2024, 07:25 PM
Lichter JayDirectorJun 03, 2024 Sale$54.75677,27937,081,0253,271,216Jun 05, 2024, 07:25 PM
Reardon TigheActing Chief Financial OfficerJun 03, 2024 Sale$54.75131,1967,182,981633,673Jun 05, 2024, 07:23 PM
Reardon TigheActing Chief Financial OfficerJun 03, 2024 Sale$54.75691,52537,860,9943,340,018Jun 05, 2024, 07:23 PM
Avalon Ventures XI, L.P.10% OwnerJun 03, 2024 Sale$54.75691,52537,860,9943,340,018Jun 05, 2024, 07:19 PM
Avalon Ventures XI, L.P.10% OwnerJun 03, 2024 Sale$54.75131,1967,182,981633,673Jun 05, 2024, 07:19 PM
Avalon Ventures XI, L.P.10% OwnerJun 03, 2024 Sale$54.75677,27937,081,0253,271,216Jun 05, 2024, 07:19 PM
Reardon TigheActing Chief Financial OfficerNov 13, 2023 Buy$5.87849,8544,988,643849,854Nov 15, 2023, 04:48 PM
Lichter JayDirectorNov 13, 2023 Buy$5.87849,8544,988,643849,854Nov 15, 2023, 04:46 PM
Avalon Ventures XI, L.P.10% OwnerNov 13, 2023 Buy$5.87849,8544,988,643849,854Nov 13, 2023, 07:11 PM
RA CAPITAL MANAGEMENT, L.P.DirectorJul 19, 2023 Buy$12.46495,0086,167,8008,117,246Jul 21, 2023, 04:31 PM
ORBIMED ADVISORS LLCDirectorDec 29, 2021 Sale$20.3040,400820,1202,258,566Dec 30, 2021, 09:00 PM
Thompson Peter A.DirectorDec 29, 2021 Sale$20.3040,400820,1202,258,566Dec 30, 2021, 08:55 PM
ORBIMED ADVISORS LLCDirectorDec 21, 2021 Sale$19.00119,4002,268,6002,295,266Dec 23, 2021, 04:13 PM
Thompson Peter A.DirectorDec 21, 2021 Sale$19.00119,4002,268,6002,295,266Dec 23, 2021, 04:08 PM
Thompson Peter A.DirectorDec 16, 2021 Sale$19.07393,3007,500,2312,403,566Dec 17, 2021, 05:16 PM
ORBIMED ADVISORS LLCDirectorDec 16, 2021 Sale$19.07393,3007,500,2312,403,566Dec 17, 2021, 05:13 PM
Thompson Peter A.DirectorJun 15, 2021 Buy$17.00705,85311,999,5012,760,366Jun 16, 2021, 06:20 PM
Reardon TigheActing Chief Financial OfficerJun 15, 2021 Buy$17.00629,41110,699,9874,479,492Jun 16, 2021, 06:11 PM
Load More Insider Transactions
Buy Sale Option Exercise
OwnerRelationshipDateValue($)
Lichter JayDirector06/03/202437,860,994
Lichter JayDirector06/03/20247,182,981
Lichter JayDirector06/03/202437,081,025
Reardon TigheActing Chief Financial Officer06/03/20247,182,981
Reardon TigheActing Chief Financial Officer06/03/202437,860,994
Avalon Ventures XI, L.P.10% Owner06/03/202437,860,994
Avalon Ventures XI, L.P.10% Owner06/03/20247,182,981
Avalon Ventures XI, L.P.10% Owner06/03/202437,081,025
Reardon TigheActing Chief Financial Officer11/13/20234,988,643
Lichter JayDirector11/13/20234,988,643
Avalon Ventures XI, L.P.10% Owner11/13/20234,988,643
RA CAPITAL MANAGEMENT, L.P.Director07/19/20236,167,800
ORBIMED ADVISORS LLCDirector12/29/2021820,120
Thompson Peter A.Director12/29/2021820,120
ORBIMED ADVISORS LLCDirector12/21/20212,268,600
Thompson Peter A.Director12/21/20212,268,600
Thompson Peter A.Director12/16/20217,500,231
ORBIMED ADVISORS LLCDirector12/16/20217,500,231
Thompson Peter A.Director06/15/202111,999,501
Reardon TigheActing Chief Financial Officer06/15/202110,699,987
Load More Insider Transactions
FUNDS WITH A POSITION IN JANUX THERAPEUTICS INC
Fund# Shares Owned% of Portfolio% ChangeInvesting Style
RA CAPITAL MANAGEMENT, L.P.9,165,6524.42%No changeOther
ORBIMED ADVISORS LLC4,275,5532.95%28.86%Other
ADAGE CAPITAL PARTNERS GP, L.L.C.2,775,6720.2%104.77%Other
BLACKROCK INC.1,693,9910.00148%-3.87%Other
GEODE CAPITAL MANAGEMENT, LLC467,5470.00163%14.54%Other
DRIEHAUS CAPITAL MANAGEMENT LLC191,0550.07%NewGrowth
RENAISSANCE TECHNOLOGIES LLC92,8990.0055%NewOther
CANDRIAM S.C.A.80,0050.02%NewOther
D. E. SHAW & CO., INC.54,6380.00176%NewOther
TUDOR INVESTMENT CORP ET AL6,4150.00154%NewEvent Driven, Other
CHANGE IN SHARES OUTSTANDING FOR JANUX THERAPEUTICS INC
STOCK BUYBACKS FOR JANUX THERAPEUTICS INC
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
03/31/2024
12/31/2023
5.00%
1Q
03/31/2024
09/30/2023
7.31%
2Q
03/31/2024
06/30/2023
17.24%
3Q
03/31/2024
03/31/2023
17.45%
4Q
03/31/2024
12/31/2022
17.95%
5Q
03/31/2024
09/30/2022
18.12%
6Q
03/31/2024
06/30/2022
18.34%
7Q
03/31/2024
03/31/2022
18.72%
8Q
03/31/2024
09/30/2021
19.24%
10Q
Load More

Period of Report: 03/31/2024

10-K/10-Q Filings: View

Previous Period
% Change in Shares
Quarter
12/31/2023
5.00%
1Q
09/30/2023
7.31%
2Q
06/30/2023
17.24%
3Q
03/31/2023
17.45%
4Q
12/31/2022
17.95%
5Q
09/30/2022
18.12%
6Q
06/30/2022
18.34%
7Q
03/31/2022
18.72%
8Q
09/30/2021
19.24%
10Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR JANUX THERAPEUTICS INC
LOADING...